Overall rank by patents
#3,791
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Vanda Pharmaceuticals Inc.
USPTO PatentsView assignee record - 96 granted patents across 14 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
96
Total patents granted
14
CPC technology areas
11.7
Avg claims per patent
+67%
5-year filing velocity
The verdict
Vanda holds 96 US patents across 14 technology areas, rank #3,791 of 50,000 tracked assignees.
- #3,791
- of 50,000 US assignees by volume
- Top 33%
- by Innovation Score (41.3/100)
- 11.7
- avg claims per patent
- +67%
- filing velocity, last 5 yrs
Portfolio overview
Vanda Pharmaceuticals Inc. has been granted 96 US utility patents between 2015 and 2025, placing Vanda Pharmaceuticals Inc. at rank #3,791 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Vanda Pharmaceuticals Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Vanda sits between Teradiode, Inc. (96 patents, rank #3,787) and Zimmer Biomet Spine, Inc. (96 patents, rank #3,795) - the closest US assignees by grant volume. The composite Innovation Score of 41.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 60 grants, compared with 36 in the 2015–2019 window, a +67% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Vanda Pharmaceuticals Inc.'s 11.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Vanda Pharmaceuticals Inc. against peers pursuing similar technology classes.
Who files at Vanda's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Teradiode
TeraDiode, Inc.
96 patents
- The Hospital for…
The Hospital for Sick Children
96 patents
- Universitat Zurich
Universitat Zurich
96 patents
- University of Seo…
University of Seoul Industry Cooperation Foundation
96 patents
- Verifone
VeriFone, Inc.
96 patents
- Wi-lan
Wi-LAN Inc.
96 patents
- Wix com
Wix.com Ltd.
96 patents
- Zimmer Biomet Spi…
Zimmer Biomet Spine, Inc.
96 patents
- Vanda Pharmaceuti… ◀
VANDA PHARMACEUTICALS INC.
96 patents
What this shows Vanda holds 96 patents at rank #3,791, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Vanda
By rank, the assignees closest to #3,791 in granted patent volume.
- Teradiode, Inc. #3,787 · 96 patents
- The Hospital For Sick Children #3,788 · 96 patents
- Universitat Zurich #3,789 · 96 patents
- University Of Seoul Industry Cooperation Foundation #3,790 · 96 patents
- Verifone, Inc. #3,792 · 96 patents
- Wi-lan Inc. #3,793 · 96 patents
- Wix.com Ltd. #3,794 · 96 patents
- Zimmer Biomet Spine, Inc. #3,795 · 96 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Vanda's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Vanda's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
41 Top 33% higher than 67% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 11 | 11.5% |
| 2016 | 5 | 5.2% |
| 2017 | 7 | 7.3% |
| 2018 | 4 | 4.2% |
| 2019 | 9 | 9.4% |
| 2020 | 13 | 13.5% |
| 2021 | 11 | 11.5% |
| 2022 | 7 | 7.3% |
| 2023 | 14 | 14.6% |
| 2024 | 5 | 5.2% |
| 2025 | 10 | 10.4% |
Which technologies does Vanda Pharmaceuticals Inc. patent most?
Top 14 of 14 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does Vanda Pharmaceuticals Inc. hold?
Vanda Pharmaceuticals Inc. holds 96 US granted patents filed between 2015 and 2025, spanning 14 technology areas.
What is Vanda Pharmaceuticals Inc.'s Innovation Score?
Vanda Pharmaceuticals Inc. has an Innovation Score of 41.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Vanda Pharmaceuticals Inc. focus on?
Vanda Pharmaceuticals Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 81 patents. The company has filed patents in 14 CPC subclasses total.
Is Vanda Pharmaceuticals Inc.'s patent filing rate increasing or decreasing?
Vanda Pharmaceuticals Inc.'s recent filing velocity is +67% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Vanda Pharmaceuticals Inc.'s patents?
Vanda Pharmaceuticals Inc.'s patents average 11.7 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Vanda Pharmaceuticals Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Vanda's 96 grants land it in the top 33% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Vanda ranks #3,791 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.